A study of the antiviral molnupiravir for high-risk people with COVID-19
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This study tests an antiviral pill called molnupiravir to see if it can prevent severe COVID-19 in people who are at high risk and cannot take Paxlovid. If you have mild to moderate COVID-19 symptoms and certain health risks, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You tested positive for COVID-19 and have had symptoms for no more than 4 days
- You have at least two COVID-19 symptoms (like cough, fever, body aches, or headache)
- You are at high risk for severe COVID-19 due to age (75+), a weak immune system, a disability, or having three or more health conditions (like diabetes, obesity, or lung disease)
- You cannot or will not take the COVID-19 pill Paxlovid (nirmatrelvir/ritonavir) for medical reasons, side effects, or because it's not available
- You are not currently hospitalized, don't need immediate hospital care, and do not have severe COVID-19 symptoms
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how well an antiviral works in the body when started early in people with COVID-19 symptoms. You may be able to join if you’re an otherwise healthy adult with confirmed infection and symptoms for less than 4 days.
This trial tests if a new medicine called ibuzatrelvir can help people with COVID-19 who have certain health risks avoid severe illness. It is for patients who cannot or choose not to take another COVID-19 pill called Paxlovid.
This trial tests a new antiviral pill, secutrelvir, for people with mild to moderate covid-19 who are at higher risk of getting seriously ill. It aims to see if the drug can prevent hospitalization or severe disease.
This trial studies whether PF-07321332 (with ritonavir) helps children under 18 who have COVID-19 at home but are at high risk of severe illness. It looks at whether starting treatment early can reduce progression to worse disease.
This trial tests whether an optimized antiviral treatment can help people with weakened immune systems who have COVID-19. It aims to find the best way to treat them to prevent severe illness.
This study looks at how well antiviral treatments work in people with weakened immune systems who get COVID-19. It focuses on patients treated with two specific antivirals and aims to understand their outcomes.
Hear when a new Coronavirus Disease (COVID-19) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.